Notes

In order to help the elderly resist the new crown, longevity researchers proposed low-dose rapamycin.
NMN (Nicotinamide Mononucleotide),

36 krypton heard today that the international academic journal aging published an article "strategies for the protection and adjustment of the elderly to reduce engineering soldiers, infection rate, severity, neutrophil and neutrophil infection mortality". The research publisher is the biotherapy research fund, a British charity that has supported and promoted the research on world aging and longevity since 2008. According to Scimago's chart, aging magazine is the top five academic journals in longevity research.
Covid-19 vaccine and treatment still have a long way to go in clinic. For the elderly, the treatment effect may decline. According to a recent BBC report, "the new crown vaccine may not be effective for the elderly.". This is not the vaccine itself, but because the aging immune system does not respond to vaccination. We see this every year when we get the flu vaccine. '"
Zhavoronkov also proposed the strategy of reusing known safe drugs for preventing sars-cov-2 infection (such as rapamycin, nicotinamide ribose, nicotinamide mononucleotide and metformin). The scientist analyzed the clinical studies of Rad001 in the healthy elderly in the past and the previous evidence that rapamycin has abnormal immune enhancement effect, and proposed further clinical trials.
He also tracked the effect of this preventive elderly protection intervention and suggested that patients be classified according to the predicted severity of covid-19.
"We use artificial intelligence to integrate into the drug discovery platform we tested to explore drug discovery and drug reuse schemes. However, covid-19 is obviously a more serious and fatal neutrophilic disease in the elderly. Dr. Alex zhavoronkov said: "The conclusions of the aging study not only help to prevent covid-19, but also many other diseases."
Homepage: https://www.esthelivsale.com/conpelson-quality